NCT02773355View on ClinicalTrials.gov

Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients

CompletedOBSERVATIONAL
Enrollment

27

Participants

Timeline

Start Date

May 16, 2016

Primary Completion Date

November 30, 2021

Study Completion Date

February 28, 2022

Conditions
Obesity
Interventions
DRUG

liraglutide 3.0 mg

Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.

Trial Locations (3)

52763

Novo Nordisk Investigational Site, México

66220

Novo Nordisk Investigational Site, Monterrey

72190

Novo Nordisk Investigational Site, Puebla City

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT02773355 - Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients | Biotech Hunter | Biotech Hunter